EMA Authorised: Intuniv (guanfacine hydrochloride) — Takeda Pharmaceuticals International AG Ireland

View source ↗

Summary

EMA authorised Intuniv (guanfacine hydrochloride) for attention-deficit/hyperactivity disorder in the European Union. The marketing authorization holder is Take…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Intuniv (guanfacine hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Attention Deficit Disorder with Hyperactivity. MAH: Takeda Pharmaceuticals International AG Ireland. Decision date: 11/12/2025